Sana Biotechnology Inc vs Synchrony Financial — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Synchrony Financial trades at $71.7 (market cap $24.69B). The key difference: Synchrony Financial is far larger — about 28.3× Sana Biotechnology Inc's market cap, and Synchrony Financial pays a 1.63% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | SYF | |
|---|---|---|
Market Cap | $873.84M | $24.69B |
Sector | Health | Financials |
52-Week High | $5.92 | $88.47 |
52-Week Low | $2.68 | $63.78 |
Enterprise Value | $848.03M | — |
Dividend Yield | — | 1.63% |
Trailing returns across standard periods
Latest headlines on both assets
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →